Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment.
The success of the targeting of amyloid-β (Aβ) oligomers through immunotherapy in Alzheimer's disease (AD) mouse models has not been translated into the clinics. The use of single-chain variable fragments (scFvs) has been proposed to prevent the potential severe effects of full-length mAbs by p...
Main Authors: | Gisela Esquerda-Canals, Joaquim Martí-Clúa, Sandra Villegas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0217793 |
Similar Items
-
Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect.
by: Laia Montoliu-Gaya, et al.
Published: (2017-01-01) -
Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer’s Disease is Affected by Aβ-ImmunoTherapy and Cognitive Stimulation
by: Alejandro R. Roda, et al.
Published: (2020-10-01) -
Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity
by: Guang-Quan Liang, et al.
Published: (2020-12-01) -
Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice
by: Alejandro R. Roda, et al.
Published: (2020-09-01) -
Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies
by: Elmira Safaie Qamsari, et al.
Published: (2017-01-01)